Amplia

Be first to know our latest company updates

Watch exclusive videos accompanying major news

Home

Science

Clinical Trial

Shareholder Services

US Shareholders

Investor Fact Sheet

Share Price

Announcements

Reports

Research Reports

Investor FAQs

Updates

Top 20 Shareholders

Investor Centre

Presentations

In the News

Video Updates

Communication

Company Overview

Corporate Directory

Corporate Governance

Board

Team

Clinical Advisers

Values

About Us

Webinars

Contact

Montserrat

Amplia Therapeutics Limited

upload.jpg

Amplia was featured on Page 5 of The Weekend Australian, in a feature by Health Editor Natasha Robinson titled ‘Peter’s pancreatic marvel: meet the luckiest man in the country.’

The story captures the remarkable journey of pancreatic cancer patient Peter Moulding - a Melbourne tradie who became the first person to achieve a pathological complete response in metastatic pancreatic cancer as part of Amplia’s ongoing ACCENT trial.

The story also features insights from Amplia's CEO and MD, Dr Chris Burns and Peter’s oncologist, Dr Prasad Cooray, from the Jreissati Pancreatic Centre at the Epworth Hospital.

Peter's story is one of courage and optimism in the face of a devastating diagnosis. Pathological complete response in metastatic pancreatic cancer is highly unusual - so rare that Dr Cooray believes only one other case has been recorded worldwide in the scientific literature.

No other patients have had such a stunning response as Mr Moulding, but Dr Cooray, who is planning to write up Mr Moulding’s case for a scientific journal, says his observation is that most of the patients in the trial have done better than had they received standard treatment.

“We don’t have the data published yet, so I don’t want to be speaking prematurely but, at the same time, I don’t want to dial down the excitement that goes with this pathological complete response, either. Every win we need to celebrate,” he says.

“This being the first pathological complete response is highly significant, I can definitely say that much. And in my career of close to 20 years, this is the first time I’ve come across that. And the only added variable in this case was the drug, the FAK inhibitor.”

The Weekend Australian | Peter’s pancreatic marvel: meet the luckiest man in the country